Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

Most disability accumulation in relapsing multiple sclerosis (MS) is not associated with overt relapses, challenging the current clinical distinction of relapsing and progressive forms of the disease, ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...

Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

The drug ocrelizumab was found effective in the treatment of multiple sclerosis in three different large-scale, multi-center trials conducted recently, reports a new study. Multiple sclerosis is an ...

Symptoms come and go in most cases of multiple sclerosis (MS), a chronic disease in which the immune system attacks myelin, the nonconductive sheath that surrounds neurons' axons. Yet 10 to 15 percent ...

– Approval based on data from the randomized, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen – – Shorter infusion time will further improve the ...